Phlow is a U.S.-based, Certified B Corporation™ leveraging advanced manufacturing processes to re-imagine the domestic production of key starting materials (KSM), active pharmaceutical ingredients (API), and finished drug products that are critical to U.S. healthcare. Focused on impact, Phlow partners with children’s hospitals, private industry, and the U.S. government to increase access to affordable, high-quality life-changing medicines through advanced manufacturing processes that are fully integrated, comprehensive, and better for the environment. Utilizing its advanced R&D labs and best-in-class, automated API cGMP facilities ranging from kilo to metric ton scales, Phlow provides customized contract development and manufacturing services for small molecule APIs to pharmaceutical and biotech companies. Phlow measures its success by its ability to drive down costs and waste, improve quality and yield, and offer a more environmentally friendly approach to manufacturing medicines that lead to healthy and resilient communities. For more, visit www.phlow-usa.com. | Phlow, a B Corporation, helps brilliant minds bring medicines to life through advanced development and manufacturing in America. Focused on innovations in drug substance development, Phlow supports government and private industry customers with scientific expertise, world-class manufacturing, and tech-enabled processes that move the industry toward a new standard as we create the future of how medicines are made. For more information, visit phlow-usa.com.
Pharmadule Morimatsu
Pharmadule Morimatsu is a global leader in modular pharmaceutical and biopharma manufacturing facilities. Pioneering modular delivery since 1986 and part of the Morimatsu Group since 2011, we design, fabricate, and deliver turnkey modular plants—combining process equipment, cleanrooms, and full facility solutions—for the life sciences and consumer products industries. Key benefits: Fixed-price certainty Flexible, scalable modules Rapid deployment worldwide (80% off-site fabrication) Reduced risk in time, cost, and quality From vaccine plants to biotech facilities, we provide fast, reliable, regulatory-compliant solutions delivered anywhere in the world. | We are a world leader in the delivery of innovative modular facilities and process equipment solutions for Life Science Industry. Originally founded in Sweden in 1986, Pharmadule was acquired in 2011 and is now part of the Morimatsu Industrial Group. This strong combination has allowed us to combine process modularization with modular facilities to deliver our clients complete turnkey solutions.
OXB (formerly Oxford Biomedica)
OXB, formerly Oxford Biomedica, is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has over 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB’s world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.
OranssiBio Ltd.
Oranssibio Ltd. | OranssiBio is a premier Contract Development and Manufacturing Organization (CDMO) strategically headquartered in Shanghai’s Free Trade Zone, specializing in advanced cell and gene therapies. We partner with biotech innovators and research institutions worldwide, delivering comprehensive, end-to-end solutions from early-stage development to clinical supply manufacturing and regulatory-compliant release. Our state-of-the-art, plug-and-play technology platforms support a diverse range of modalities, including: • Plasmid DNA • Lentivirus & Adeno-Associated Virus (AAV) • mRNA Therapeutics • Cell Therapies: CAR-T, TILs, NKs, iPSCs, and MSCs With a focus on quality, speed, and cost efficiency, OranssiBio accelerates the translation of groundbreaking therapies from bench to bedside, empowering our partners to bring life-changing treatments to patients faster and more effectively.
Oncomed Manufacturing a.s.
We are part of CDMO medac group – your reliable partner specialized in aseptic processing of injectables in clinical and commercial scale. We work is strategic partnership with our clients to provide customized solutions for aseptic manufacturing. | CDMO committed to delivering reliable, flexible support across the entire pharmaceutical value chain. Our capabilities include: • Manufacturing high- and low-potency injectables (vials and syringes) for international markets • Production of small- and large-molecule therapeutics, including complex biologics such as antibody-drug conjugates (ADCs) and oligonucleotides • Scalable batch production, tailored from clinical development through to full commercial supply | x
NorthX Biologics
We offer services and support in the development and manufacturing of biologics used in vaccines, gene therapy and other advanced applications. Let’s journey together. | Nestled in Sweden’s life sciences heartland, NorthX Biologics has been at the forefront of biologics manufacturing and process development since 1992. Our rich heritage in Good Manufacturing Practice (GMP) is not just a testament to our enduring commitment to quality but also to the trust that the biotech community has placed in us for nearly three decades. Our expertise spans a comprehensive spectrum of biologics, including plasmids, proteins, mRNA, viral vectors cell therapy, and an array of other advanced therapeutic entities. It is our relentless pursuit of excellence and innovation that led to our recognition in 2021 as a national innovation hub for advanced therapeutics and vaccines by the Swedish Government, a milestone that underscores our role in shaping the future of healthcare. We are more than a CDMO; we are pioneers and partners in the truest sense. At NorthX Biologics, we believe in embarking on a collaborative journey with our clients, navigating the complexities of biologics and growing along the way. Let’s journey together to turn visionary science into life-changing treatments. Visit us to learn more at nxbio.com | Nestled in Sweden’s life sciences heartland, NorthX Biologics has been at the forefront of biologics manufacturing and process development since 1992. Our rich heritage in Good Manufacturing Practice (GMP) is not just a testament to our enduring commitment to quality but also to the trust that the biotech community has placed in us for nearly three decades. Our expertise spans a comprehensive spectrum of biologics, including plasmids, proteins, mRNA, viral vectors cell therapy, and an array of other advanced therapeutic entities. It is our relentless pursuit of excellence and innovation that led to our recognition in 2021 as a national innovation hub for advanced therapeutics and vaccines by the Swedish Government, a milestone that underscores our role in shaping the future of healthcare. We are more than a CDMO; we are pioneers and partners in the truest sense. At NorthX Biologics, we believe in embarking on a collaborative journey with our clients, navigating the complexities of biologics and growing along the way. Let’s journey together to turn visionary science into life-changing treatments.
Northway Biotech
Northway Biotech is a global end-to-end biologics CDMO supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company’s wide-ranging expertise and vertically integrated service offerings translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities, while ensuring full process and product compliance at all stages of research, development, and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius (Lithuania) and Waltham, MA (USA). | Northway Biotech is a global end-to-end CDMO specializing in protein-based biologics and gene therapies. With over 20 years of experience and 180+ successful client programs, we provide integrated solutions – from cell line development to manufacturing cGMP Drug Substance and Drug Product. Our cGMP facilities in Vilnius, Lithuania, and Waltham, MA, support rapid, scalable manufacturing from early development through clinical and commercial phases. Known for scientific excellence, regulatory compliance, and a collaborative approach, Northway Biotech helps clients accelerate biopharmaceutical process development and manufacturing with speed, precision, and flexibility. | Northway Biotech is a leading biologics CDMO specializing in protein-based biologics and gene therapies, offering comprehensive, end-to-end biopharmaceutical development and manufacturing services. With deep expertise in cell line development, process optimization, and cGMP manufacturing, Northway Biotech supports programs from early-stage development through to commercial production. Founded in 2004, the privately held company operates state-of-the-art facilities in Lithuania and the United States, delivering high-quality, compliant solutions tailored to each client’s unique needs. For further information, please visit www.northwaybiotech.com.
NOF CORPORATION
NOF CORPORATION is the leading commercial supplier of drug delivery products such as activated PEGs, lipids and ultrapure Polysorbate 80. Our cutting edge products include Pendant type single molecule PEG linkers for ADCs and SS-lipids for nucleic acid/gene delivery and vaccines.
NJ Bio
NJ Bio, Inc. is a CRO/CDMO specializing in integrated chemistry and biology services for ADCs and other complex bioconjugates. We offer comprehensive solutions spanning discovery, development, characterization, optimization, and bioanalysis, complemented by robust in vitro and in vivo capabilities to support translational decision-making. We provide toxicology, pharmacology, PK, and immunology services to support safety assessment, efficacy profiling, and translational development of ADC and bioconjugate programs. Our expertise in synthetic chemistry, bioconjugation, linker design, and bioanalytical capabilities, ensure seamless support across the entire drug development process and help accelerate ADC programs to become front-line treatments for cancer patients. | NJ Bio, Inc. is a CRO/CDMO that provides high-quality integrated chemistry and biology services to clients mostly from the biotech and pharma sectors. Main service areas include antibody-drug conjugates, bioconjugation, and multistep organic synthesis. The company is headquartered in Princeton, New Jersey, with additional chemistry facilities in Bristol, Pennsylvania. NJ Bio’s facility in Princeton, NJ, occupies ~ 80,000 sq ft of laboratory and office space, with specialized laboratory suites for highly potent compound synthesis, bioconjugation, bioassays, and analytical studies. The facility is very well equipped with instrumentation required for ADC- and bioconjugation-related work. | NJ Bio, Inc. is a CRO/CDMO specializing in integrated chemistry and biology services for ADCs. We offer comprehensive solutions for ADC development, characterization, optimization, and bioanalysis. Our expertise in synthetic chemistry, bioconjugation, linker design, and bioanalytical capabilities, ensure seamless support across the entire drug development process and help accelerate ADC programs to become front-line treatments for cancer patients. | NJ Bio, Inc., is a CRO that provides high-quality integrated chemistry and biology services for ADCs, bioconjugates and nucleic acid-based therapeutics. We strive to be a beacon of excellence in contract research, development and manufacturing by providing cutting-edge biopharmaceutical and advanced chemistry services. Backed by deep expertise in bioconjugation & chemical synthesis, we add value to targeted therapeutic programs through integrated services in conjugation, process development, characterization, and bioanalysis of complex molecules.